Monitor upcoming MICVO data readouts (mid-2026 and 2H26) for potential catalysts; limited cash runway suggests financing risk if trials delay.
Price Chart
Executive Summary
Pyxis Oncology reported Q1 2026 EPS of -$0.37, missing consensus of -$0.35 by 5.7%. The clinical-stage biotech has $42.5M cash runway into Q4 2026 and reiterated MICVO Phase 1 monotherapy data for mid-2026 and combination data for 2H26. The modest earnings miss is typical for pre-revenue companies and overshadowed by pipeline milestones.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.37 vs consensus -$0.35 (5.7% miss)
- Cash and investments $42.5M, runway into Q4 2026
- MICVO Phase 1 monotherapy update expected mid-2026, combination data 2H26
- No revenue (clinical-stage biotech)
Financial Impact
Net loss of $23.3M in Q1 2026, up from $21.2M in Q1 2025; cash burn $42.5M remaining
Risk Factors
- Cash runway only into Q4 2026, possible dilution if milestones slip
- Clinical trial failure risk for MICVO
- Pre-revenue stage with no near-term revenue prospects
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294764 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $3.38 $3.34 | ▼ −1.18% | ▼ −0.09% | $2.14 (−36.54%) |
Sep 8, 2026 24d ago | 8-K | $3.89 $3.33 | ▼ −14.40% | ▼ −13.28% | $2.14 (−44.86%) |
Aug 28, 2026 5w ago | EFFECT | $3.23 $3.89 | ▼ −20.43% | ▼ −20.32% | $2.14 (+33.59%) |
Aug 13, 2026 7w ago | 8-K | $3.01 $3.12 | ▲ +3.65% | ▲ +5.62% | $2.14 (−28.74%) |
Jul 2, 2026 13w ago | 8-K | $2.63 $2.64 | ▲ +0.38% | ▼ −0.55% | $2.14 (−18.44%) |
Jun 30, 2026 13w ago | 144 | $2.85 $3.07 | ▲ +7.72% | ▲ +7.46% | $2.14 (−24.74%) |
Jun 30, 2026 13w ago | Press Release | $3.01 $2.46 | ▼ −18.27% | ▼ −18.88% | $2.14 (−28.74%) |
May 14, 2026 20w ago | 8-K | $2.21 $1.94 | ▼ −12.22% | ▼ −11.50% | $2.14 (−2.94%) |
May 14, 2026 20w ago | Press Release | $2.21 $1.94 | ▼ −12.22% | ▼ −11.50% | $2.14 (−2.94%) |
Apr 30, 2026 22w ago | DEFA14A | $1.70 $2.26 | ▲ +32.94% | ▲ +31.21% | $2.14 (+26.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access